AI
Isomorphic Labs lands $5B to advance AI-designed drugs toward human trials
The DeepMind spinout has secured a major funding round as it prepares to test its AI-discovered drug candidates in clinical settings.
TechCrunch — AI
Isomorphic Labs, the AI-powered drug discovery company created when it split from Google's DeepMind in 2021, has closed a $5 billion Series C funding round. The capital injection positions the firm to begin clinical testing of its AI-designed pharmaceutical candidates.
Funding leadership and backing#
Greenoaks and Sequoia Capital co-led the investment, while venture firms Andreessen Horowitz and others joined as new participants. The round also attracted every previous backer, including Alphabet's venture arms GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
How the technology works#
The company operates an AI platform that simulates molecular chemistry at scale, enabling rapid design of novel drug candidates. Its approach builds on DeepMind's landmark AlphaFold protein-folding AI model, which revolutionized how scientists predict protein structures from genetic sequences alone. Early-stage results show promise in oncology and immunology, and the firm has forged partnerships with major pharmaceutical manufacturers including Eli Lilly, Novartis, and Johnson & Johnson.
What's next#
The fresh capital will accelerate development of the core drug-design engine and expand into additional therapeutic areas. This funding round follows a $2.1 billion Series B completed just six months prior, underscoring investor appetite for the company's approach. While Isomorphic kept its new valuation private, reports earlier this month suggested negotiations pegged it at approximately $50 billion.
Leadership milestone#
The funding announcement coincides with founder and CEO Demis Hassabis stepping back from his day-to-day role leading DeepMind to concentrate on Isomorphic—a shift he combined with taking on a chairman position at the AI research lab. Hassabis and fellow DeepMind scientist John Jumper shared the Nobel Prize in Chemistry for their foundational work on AlphaFold.

